Ashutosh Raghuvanshi
Managing Director and CEO, Fortis Healthcare
Promise Delivery Record
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY25Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Fortis Healthcare · Q1 FY25Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Fortis Healthcare · Q1 FY25Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Fortis Healthcare · Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q4 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q4 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q3 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY24Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Fortis Healthcare · Q2 FY24Notable Quotes
We are doing direct marketing there, and opening some information centers in these geographies to increase this business.
We expect we will continue to do better on the margin expansion side as our units are becoming matured.
We have witnessed a healthy start to the financial year 2026. Our hospital business continues to perform well, both in terms of revenue and margins.
These facilities have a good potential. They are located well in the micromarkets they are in. We believe that the full potential of these hospitals has not yet been realized.
We have not considered that when we say that we are expecting about 2% of increase in our profitability profile. These hospitals are important statistically for the long term, but in the short term, whatever guidance has been given is not considering that these hospitals have come to a 20-plus category.
Our consolidated operating EBITDA increased 32% to INR 375 crores, delivering a margin of 19.4% versus 16.9% in Q3 of Financial Year 2024.
Our consolidated operating EBITDA increased 31.9% to INR 435 crore, delivering a margin of 21.9% versus 18.6% in Q2 of Financial Year 24.
Our performance in Q1 financial year 2025 has been impressive, showing a significant improvement over the previous year.
We are maintaining our guidance which we have given earlier. We could demonstrate around 2% EBITDA margin improvement over the last year. I am expecting similar type of slightly better than this in the next financial year.
We are working with the private equity investor to come out with a solution for this particular thing. So, one option is for the revival of the IPO, so that we are working with bankers along with the private equity investors for revival of the IPO.
The healthcare industry remains so much under the glare of media and public interest groups, that the industry has to calibrate the price changes very, very carefully.
Our business performance in Q3 has been satisfactory considering the seasonal impact of festivals in some of our key geographies.